CCS
MDGL icon

Crosspoint Capital Strategies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Crosspoint Capital Strategies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-124
Closed -$11.4K – 54
2017
Q4 		$11.4K Buy
+124
New +$7.08K 0.01% 80

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Crosspoint Capital Strategies's MDGL Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2018, closing a stake of 124 shares — an estimated $11.4K sold.

Crosspoint Capital Strategies first reported a position in MDGL in Q4 2017 and held it in 1 quarter. The position peaked at $11.4K in Q4 2017. 100 funds tracked by Wall St. Rank hold MDGL as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining Madrigal Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 124 Madrigal Pharmaceuticals shares in Q1 2018, an estimated $11.4K.
  • Crosspoint Capital Strategies first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Madrigal Pharmaceuticals position peaked at $11.4K in Q4 2017.
  • 100 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.